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economic burden on affected countries. There are currently no vaccines or effective drugs available for
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Abstract
The recent emergence and re-emergence of alphaviruses, in particular the chikungunya virus
(CHIKV), in numerous countries has invoked a worldwide threat to human health, while
simultaneously generating an economic burden for affected countries. There are currently no
vaccines or effective drugs available for the treatment of the CHIKV, and with few lead compounds
reported, the vital medicinal chemistry is significantly more challenging. This study reports on the
discovery of potential inhibitors for the nsP3 macro domain of CHIKV using molecular docking,
virtual screening and molecular dynamics simulations, as well as work done to evaluate and
confirm the active site of nsP3. Virtual screening was carried out based on blind docking as well as
focused docking, using the databases of 1541 compounds from NCI Diversity Set II, to identify hit
compounds for nsP3. The top hit compounds were further subjected to molecular dynamic
simulations, yielding a greater understanding of the dynamic behavior of nsP3 and its complexes
with various ligands, concurrently confirming the outcomes of docking, and establishing in silico
lead compounds which target the CHIKV nsP3 enzyme.
Keywords: chikungunya virus, molecular docking, virtual screening, molecular dynamics
simulations, nsP3 macro domain.
Introduction
Chikungunya virus (CHIKV) is an emerging mosquito-borne arthrogenic member of the alphavirus
genus from the family Togaviridae, which has caused widespread outbreaks of debilitating human
disease in the last 5 years [1]. The resulting chikungunya fever (CHIKF) was first described in 1952
[2], and has been identified in nearly 40 countries. It was listed in 2008 as a US National Institute of
Allergy and Infectious Diseases (NIAID) category C priority pathogen due to its high morbidity and
mortality rates and thus major impact on health [3,4].
After the initial mosquito bite, symptoms of chikungunya fever infection generally start in 4–7
days, and usually occur in two phases: an acute followed by a second persistent (chronic) stage that
causes disabling polyarthritis [5]. Acute infection lasts 1–10 days and is characterized by a painful
polyarthralgia, high fever, asthenia (weakness), headache, vomiting, rash, and myalgia [6]. The
persistent chronic stage of CHIKF is characterized by polyarthralgia lasting from weeks to years
[7]. Additional symptoms include neurological disorders such as encephalitis, myeloneuropathy,
peripheral neuropathy, myelopathy and myopathy [8].
The CHIKV genome consists of a single stranded, positive-sense RNA genome with two open
reading frames (ORFs) [9], and is approximately 11.8 Kb in size. The ORF at the 5ʹ end encodes
two polyproteins, the precursors of the non-structural proteins. The second ORF at the 3ʹ end
encodes the structural proteins, the capsid (C), envelope glycoproteins E1 and E2 and two small
cleavage products (E3, 6K). CHIKV starts its life cycle by entering the target host cells through pHdependent endocytosis via a receptor-mediated interaction [10] in an analogous manner to other
members of the Alphaviruses genus.
The medicinal chemistry of CHIKV has recently been reviewed [11]. That review highlighted the
extreme lack of available chemotherapeutics that show any inhibitory effects against the virus. In

contrast, the emergence of numerous models and solved crystal structures of CHIKV proteins
points to enormous possibilities for directed drug design. Notable among the available targets are
the envelope proteins [12-15] and the non-structural proteins of CHIKV, which play an important
role in the formation of the transcription/replication complex of the virus [15,16]. Among these,
nsP3 is considered an attractive target for drug design because of its participation in the early stage
of the transcription process of viral replication, even though the specific functions, roles, and
activities of the nsP3 protein remain elusive [16,17].
To date, there have been relatively few studies on the functions, roles and activities of alphavirus
nsP3 proteins [11,18-20]. Studies based on the Sindbis virus reported that nsP3 phosphoprotein is
an essential component of the viral replication and transcription process. Functional analysis of the
effects of mutations of nsP3 on the RNA synthesis demonstrated that the mutations can cause a loss
of capacity for minus-strand synthesis or a failure to increase plus-strand synthesis. Strikingly, a
change in G4303 implying an alteration from Gly to Ala68 and leading to a modification to the HisAla-Val peptide was predicted to form part of the active site of the conserved nsP3 macro domain
[19]. However, no effect of the mutations on the ADP-ribose binding site was found [17]. The nsP3
protein consists of two domains, the N-domain and the C-domain [16,17]; the N-domain is highly
conserved but the C-domain is not [17]. The C-domain is phosphorylated at up to 16 positions on
serines and threonines [11,17]. The role of this phosphorylation is still not clear, but deletion of the
residues involved in the phosphorylated process can decrease the level of RNA sysnthesis
[11,17,21]. The N-domain, in which the region comprising the first 160 residues is called the Xdomain or a macro domain , is commonly present in eukaryotic organisms, bacteria, archea and in
many positive-strand RNA viruses such as hepatitis E, rubella, coronavirus and alphaviruses [16].
The alphavirus macro domain has a highly positive charged patch on the surface of the protein at
the crevice of ADP-ribose 1"-phosphate active site and its periphery [17]. The other side of the
protein, far from the active site, possesses a negative charge. Thus, the nsP3 macro domain is
considered to complex with ADP- ribose derivatives and RNA. It is also believed to control the
metabolism of ADP-ribose 1"-phosphate and/or other ADP-ribose derivatives with regulatory
functions in the cell [11,22].
The crystal structure of the nsP3 macro domain of CHIKV was solved in 2010 [17]. The
asymmetric unit of CHIKV includes four molecules. The macro domain consists of six-stranded βsheets and four α-helices, and the positions of the α-helices are highly conserved. Also present is
the ligand ADP-ribose, and the active site of nsP3 macro domain is considered the binding site for
this ADP-ribose ligand [16,17]. This crevice is at the top of the β-strands 2, 4 and 5 and is
surrounded by two loops between β2-α1 and β5-α3. Since there is very little information available
on the nsP3 macro domain and its inhibitor, the current study used computational approaches
(including molecular docking and virtual screening) to discover potential compounds that inhibit
nsP3 in CHIKV. Furthermore, in order to understand both the static structures and the dynamic
information, molecular dynamics simulations were performed to gain a greater understanding of the
behavior of nsP3 and how it changes upon the binding of small molecules. The results of the study
were analyzed and compared with previous data to gain a deeper understanding of the atomic
structure of the nsP3 macro domain and its complexes, as well as to confirm the interactions and
results from docking.
Material and methods
Molecular docking and virtual screening
Molecular docking and virtual screening were conducted using AutoDock Vina (version 1.5.4) [23].
In the current study, the protein was treated rigid while the ligands were fully flexible. The protein
was prepared by retrieving the 3D crystal structure of the nsP3 macro domain protein from the

Protein Data Bank (PDB id: 3GPG) and this was used as the receptor for docking. The ligand ADPribose was extracted from the complex crystal structure (PDB id: 3GPO) whereas other ligands
employed for virtual screening were downloaded from the website of the Diversity Set II chemical
library of the National Cancer Institute (NCI). This library was selected as it contains diverse druglike compounds and potential hits can be ordered from the Open Chemical Repository Collection
for activity testing. The protein was subsequently minimized by applying the CHARMM force field
in the Accelrys Discovery Studio 2.0 software package [24]. The steepest-descent algorithm with
3,000 steps was used to relax the structure and remove steric overlaps. With a Cα RMSD of 0.59 Å
between the minimized structure and the X-ray structure, the minimized structure was utilized for
the docking process. Polar hydrogen atoms were added and the Kollman charges were defined with
AutoDock Tools (version 1.5.4). The key docking parameters include the location of the docking
site (center x, y, z) and the size of the grid box. The docking protocol was established by re-docking
the ADP-ribose into nsP3 as seen in the co-crystal structure (3GPO). In the docking with ADPribose, box dimensions of 16×16×16 Å was used, centered at the crystallographically determined
binding site. In virtual screening, the location and the size of the grid box were carefully
investigated via blind docking (in which the box is sufficiently large to cover the whole protein) and
focused docking (in which a smaller box was centered on the potential binding site of interest).
Blind docking can reveal potential binding sites in nsP3, but it can also suffer convergence
problems during sampling. The MetaPocket program was also used to predict potential binding sites
of nsP3 other than the active site [25]. After docking, the results were analyzed and compared with
available experimental data. The top ten compounds (“hit”) were identified according to their
binding affinities using the default scoring function in Vina. The modes of interaction between l the
igands and the protein were analyzed in Accelrys Discovery Studio 2.0. The drug-like properties of
these compounds were subsequently evaluated using the Lipinski Guidelines [26].

Molecular dynamics simulations of the docked complexes
In order to evaluate the stability of the docked complex and better characterize the ligand-nsP3
interactions, equilibrium molecular dynamics (MD) simulations were carried out with the NAMD
package [27]. The protein atoms were treated with the CHARMM22 force field [28], and the
corresponding parameters for the ligands were generated with AmberTools [29]. MD simulations
were carried out for the apo state (PDB id: 3GPG) and the five ligand-nsP3 complexes. The systems
were solvated in a cubic box of TIP3P water molecules and neutralized by sodium counterions to
achieve the physiological ionic concentration of 0.15 M with NaCl. The total number of atoms
(including protein, water and counterions) in the CHIKV system was about 18,000, and the size of
water box was about 58×58×58 Å. All simulations were performed under the periodic boundary
conditions at a temperature of 298.15 K and a pressure of 1 atm. Temperature and pressure coupling
were maintained with the Langevin algorithm. A particle mesh Ewald algorithm was used to
calculate the electrostatic interactions [30]. The cutoff distance for van der Waals interactions and
the pairlist distance were 12 and 13.5 Å, respectively. The systems were minimized and then
equilibrium simulations with weak harmonic restraints on the heavy atoms were performed for 3 ns.
The production runs were continued for 20 ns. The trajectories were saved every 1 ps. The resulting
trajectories were analyzed using the CHARMM [31] and VMD 1.9 programs [32].
Results
Validation of the docking protocol by re-docking with ADP-ribose
The docking protocol was evaluated by re-docking ADP-ribose into nsP3, and the outcome was
compared with the available co-crystal structure (PDB id: 3GPO). The ligand conformations were
ranked in terms of their predicted binding affinities using the default scoring function in Vina (see

Table S1 of the “Electronic supplementary material,” ESM). The best-docked pose had a binding
affinity of -10.2 kcal mol-1. The hydrogen bonds formed between ADP-ribose and nsP3 are shown
in Fig. 1. It is evident that there were interactions with 11 residues in the active site of nsP3: Ile11,
Ala23, Asn24, Asp31, Val33, Leu108, Gly112, Val113, Tyr114, Tyr142 and Arg144. Most of the
hydrogen-bond donors came from the protein residues, with the corresponding acceptors deriving
from the ADP-ribose. In addition, the diphosphate component of ADP-ribose showed the strongest
interaction of any part of this ligand.
Moreover, the accuracy and reliability of docking was evaluated by superimposing the docked
structure on the co-crystal structure. The heavy-atom root mean square deviation (RMSD) was 0.6
Å, smaller than the 2.0 Å often used as a criterion in correct bound structure prediction [33] (Table
S1 of the ESM and Fig. 2) indicating that the molecular docking reproduced the binding mode in
the co-crystal structure. Comparison of the interactions indicated by the docking results with
published data (Table 1) confirmed there was good agreement in the key interactions and showed
that this docking protocol was able to reproduce the correct pose (Fig. 2).
Identification of potential inhibitors using virtual screening
In an effort to identify potential inhibitors (hit compounds), 1541 compounds in NCI Diversity Set
II were screened by docking them with the nsP3 of CHIKV. Virtual screening (VST) was carried
out using three different setups. The first was a focused docking centered around the ADP-ribose
binding site (pocket 1: VST1 and VST2). The second setup was a blind docking centered either at
the middle of the ADP-ribose binding site (VST3) or the protein (VST4) with the box made large
enough to cover the whole protein. The third setup was a focused docking centered on the binding
sites predicted by MetaPocket (pocket 2: VST5; pocket 3: VST6). The top ten compounds for each
VST based on their binding affinities are listed in Table S2 of the ESM.
In the focused dockings that targeted binding pocket 1 (the ADP-ribose binding site; VST1 and
VST2), the top hits were NCI_25457 (-10.8 kcal mol-1) and NCI_345647_a (-10.9 kcal mol-1).
Among the top ten hits, four are shared between VST1 and VST2, which differ in the size of the
grid box used. Given our interest in finding more inhibitors as well as other potential binding sites
in the structure of nsP3, we used the blind docking to dock into the entire protein, with the grid box
centered on the middle of either the ADP-ribose binding site (VST3) or the protein (VST4). For the
blind docking (VST3 and VST4), six of the top ten hits are common to VST3 and VST4, and the
binding affinities were reproduced to within 1.0 kcal mol-1. This indicates that the blind dockings
are likely to have converged. The results show that most of the top ten hits fitted well in pocket 1,
and this pocket can accommodate ligands of different sizes. However, ligands having bulky
structures, such as NCI_293778, NCI_58052 and NCI_61610 (common to the top ten hits of both
VST3 and VST4), protruded from the binding site. Furthermore, the other pockets surrounding
pocket 1 may serve as alternative binding sites for potential inhibitors.
By comparing the results from the blind dockings with the pockets predicted for nsP3 using
MetaPocket, pocket 2 and pocket 3 were identified, and focused docking at pockets 2 (VST5) and 3
(VST6) was conducted. Screening at VST5 and VST6 produced hits that had already been
identified in previous screens, along with some new hits (Table S2 of the ESM). Pockets 1 and 3
share a number of interacting residues, including Asn24, Asp31, Val33, Gly112, Val113 and
Tyr114. In contrast, pocket 2 was located on the opposite side and behind pocket 1, and comprised
the residues His1, Pro2, Ser3, Tyr4, Met132, Asp133, Ser134, Thr135, Asp136, Ala137, Asp138,
Val139, Arg159, Thr160, Ile156 and Gln157. The location of the pockets in nsP3 and the location
of the different ligands in the three pockets are illustrated in Figs. 3 and 4. Most of compounds
effectively occupy pockets 2 and 3 and participate in significant interactions. Ligands NCI_127133
(-8.3 kcal mol-1) and NCI_670283 (-10.6 kcal mol-1) bind in pockets 2 and 3 as well as pocket 1, but

in different conformations. Interestingly, the ligand NCI_293778 would be able to bind into all
three pockets, although it may be inferred that the pocket 1 is more favorable for binding, with a
binding affinity of -10.5 kcal mol-1 compared to -9.4 kcal mol-1 (pocket 3) and -8.3 kcal mol-1
(pocket 2).
For the virtual screening, it is worth mentioning that the changes in size of the grid box and its
location affected the search process in Vina. Increasing the dimensions of the box is likely to be
better suited to larger molecules. For instance, in the blind docking (VST3 and VST4), NCI_61610
(-11.1 kcal mol-1) was identified as a top ten hit, but it is not one of the top ten hits for VST1 and
VST2. The locations of the three binding sites along with the top five compounds obtained from
VST are displayed in detail in Fig. 3 (for more information, see Fig. S1 of the ESM). It is also
interesting that the majority of the hit compounds show tighter binding in pocket 1 than in pocket 2.
Detailed analyses of the interactions between the ligands and protein target were carried out by
characterizing the hydrogen bonds and hydrophobic contacts [34]. The results show that hydrogenbonding interactions play a more important role in the binding to pocket 1, whereas hydrophobic
contacts are responsible for the interactions associated with the binding to pocket 2. In agreement
with this, it was previously reported [16] that the residues Ser110, Thr111, Gly112 and Tyr114
define pocket 1 and are key residues in interactions with ligands. In addition, we found that these
residues also define pocket 3.
Investigation into the stability of the protein and its complex using molecular dynamics simulations
The top five hit compounds NCI_61610, NCI_25457, NCI_345647_a, NCI_670283 and
NCI_127133 from each screening were subsequently subjected to molecular dynamics simulations
(Table 2). MD simulations were undertaken to investigate the dynamic behaviors of protein nsP3
and its complexes and to obtain the precise binding modes [35]. MD simulations were carried out
with the NAMD package with the CHARMM force field for 20 ns following 3 ns of equilibrium
simulations.
In order to assess the overall stability, RMSD values with respect to the starting structure were used
as the major criterion. The backbone RMSD curves for nsP3 and its complexes with different
ligands with respect to the starting structure were not significantly different from each other (Fig.
5). All systems were relatively stable throughout the simulations after reaching equilibrium within 3
ns. Hence, data taken from the trajectories in the last 20 ns will be used for further analysis.
The root mean square fluctuation (RMSF) of the Cα atoms of each residue was calculated using the
data from 20-ns trajectories of the protein nsP3 and its complexes (Fig. 6). The RMSF profiles of
the apoprotein and the complexes were similar. However, subtle differences were observed for a
few regions, including the loop at residues 31-34. The residues comprising the binding pockets
were quite stable during the simulations, with fluctuation of < 1.0 Å. It is worth noting that when
the three ligands NCI_61610, NCI_25457 and NCI_345647_a were bound to the protein at pocket
1, the RMSFs for the binding loop region 31-34 were noticeably smaller than those seen for the
apoprotein. The RMSF for this loop was not significantly perturbed when the ligands NCI_670283
and NCI_127133 were bound to pockets 3 and 2, respectively.
Interaction between the ligands and the protein nsP3
A detailed analysis of the hydrogen-bonding (H-bond) interactions and hydrophobic contacts
between the ligands and nsP3 was carried out. Simple geometric criteria were used to define a
hydrogen bond: a distance between proton donor (D) and acceptor (A) atoms of <3.5 Å and an
angle D-H…A of >1200 [16]. If the H-bond occupation percentage was >50%, they were
considered to arise from the medium, whereas strong hydrogen bonds are considered to be present

for H-bond occupations of greater than 75% [16]. Hydrophobic contacts between the carbon atoms
of non-polar parts of protein residues were also monitored, with a cutoff distance of 4.0 Å assumed
[36,37].
Complementary to the results of the docking (where the protein was kept rigid), molecular
dynamics simulations revealed that when the ligands bind to nsP3, the ligand or/and the residues in
the binding pockets fluctuate, with the residues adapting their structures to better accommodate the
ligands by forming H-bonds and/or hydrophobic contacts. This can be illustrated by superimposing
the complex before the simulations (at 0 ns) on the complex after the simulation (at 23 ns); see Fig.
7). Not surprisingly, the figure shows that some residues, such as Val33, Val113, Tyr114, Arg144
and Trp148 (for ligands binding to the pocket 1; see Fig. 7a, 7b and 7c), display noticeable
movement upon binding. For ligands NCI_127133 (pocket 2) and NCI_670283 (pocket 3), the
results showed that the fluctuations of residues Ala1, Pro2 and Tyr4 (in the pocket 2) and residues
Ala22, Val33, Val113 and Tyr114 (pocket 3) were required for a correct fit into nsP3.
Key residues forming hydrogen bonds and hydrophobic contacts between nsP3 and ligands
Hydrogen-bonding analyses revealed that the binding of each investigated ligand to the protein is
stabilized by a number of hydrogen bonds, except ligand NCI_127133 (Table 3). We can infer that
the binding site at pocket 1, where NCI_61610, NCI_25457 and NCI_345647_a bind, is the most
favorable place for ligands to form hydrogen bonds (Fig. 8). There are three strong hydrogen bonds
between ligand NCI_61610 and residue Asn24 (98%), Tyr114 (92%) and Gly112 (88%) in pocket
1, but only one strong and one moderately hydrogen bond between NCI_670283 and Thr111 (78%)
and Gly112 (66%) in the pocket 2 (Fig. 7). In contrast, pocket 3 is unlikely to be favored for
binding, as no H-bonds with occupations of >10% were identified.
Furthermore, the residues in the region 110-114 of the protein are key residues that are responsible
for forming the hydrogen bonds between the protein and the ligands in binding pockets 1 and 3.
Most of them serve as hydrogen bond donors, except in the complex nsP3-NCI_61610, where
residue Thr111 serves as an acceptor. This observation is in close agreement with the results of
earlier simulations and experimental data [16]. In addition, it emerged that the structures of
NCI_61610 and NCI_345647_a are more polar than the other ligands, so more hydrogens bonds
were found in complexes involving them than in complexes involving the other ligands.
The nsP3 residues that were found to interact with the ligands through hydrophobic contacts are
listed in Table 4. It is worth noting that four residues, namely Val33, Val113, Tyr114 and Trp148,
play a crucial role in stabilizing the complexes by facilitating hydrophobic interactions between the
ligands and nsP3 at the binding pockets 1 and 3, while Ala1, Pro2 and Tyr4 are important in pocket
2. The solvent accessible surface areas (SASA) were calculated to monitor the possible changes in
the salvation environment upon ligand binding (Table 5). We expected to see that the SASA for
hydrophobically interacting residues in the protein-ligand complex will decrease compared to those
in apoprotein. In pocket 1, when the ligands bind to protein, it can be seen that the solvent surface
of residue Tyr114 decreases from 70.2 Å2 in the apo nsP3 to 63.4 Å2 for the nsP3-NCI_61610
complex and 63.8 Å2 for nsP3-NCI_345647_a complex. Also, the SASA of Val33 reduces from
68.8 Å2 in the apo state to 57.4 Å2 and 52.9 Å2 for the bound state in nsP3-NCI_25457 and
NCI_345647_a, respectively. However, it is apparent that the changes in SASA for Val33, Val113
and Trp148 are not consistent for different ligands. This can be rationalized by noting that these
residues are able to form not only hydrophobic contacts but also polar hydrogen-bonding
interactions. Thus, the change in SASA is compromised by polar interactions, and both types of
interaction modulate the SASA.

In order to probe the effects of the static protein structure used in the docking, multiple docking
simulations and virtual screening were carried out based on the sampled conformations of protein
nsP3-NCI_61610 at different simulations times (5, 10, 15, and 20 ns). These results are listed in
Tables S3 and S4 of the ESM. The binding affinities observed in these docking runs (Table S3 of
ESM) were not significantly different from those obtained in previous dockings based on the X-ray
structure. Additionally, the binding modes observed in the dockings based on the X-ray structure
are similar to those obtained based on the MD sampled structures. Most of the top hits in the virtual
screening were the same compounds as those identified in the previous screening, although there
were some new hits too. This indicates that the docking results were similar for different static
structures of the nsP3 protein.
Discussion and conclusion
So far, little information on the nsP3 macro domain and its inhibitors has been reported. The present
study is of great importance in relation to identifying novel inhibitors of the chikungunya virus. It is
also the first to combine molecular docking, virtual screening and molecular dynamics simulations
to identify potential inhibitors that target CHIKV by taking advantage of the recently determined
high-resolution crystal structure of nsP3 in complex with ADP-ribose. Considering the presence of
positive charge at the ADP-ribose binding site, this binding pocket may have the tendency to
accommodate negatively charged ligands, which may not have acceptable pharmacokinetic
properties. Therefore, we decided to identify all possible binding pockets based on the available
methods. We first re-docked the ADP-ribose and successfully reproduced the bound structure and
the key residues for interactions in the ADP ribose binding pocket. It was evident that the binding
affinity of ADP-ribose was less than -10 kcal mol-1, showing that this negatively-charged ligand
binds very tightly to nsP3. This study also demonstrates that the current docking protocol utilizing
Autodock Vina is a robust approach for reproducing experimentally determined binding modes.
Subsequently, virtual screening with the NCI Diversity Set II was undertaken to identify potential
novel inhibitors that target CHIKV. In addition to the well-characterized adenine binding pocket
(pocket 1), two additional binding pockets (pockets 2 and 3) were identified through blind docking
and using MetaPocket. Pocket 3 partially overlapped with pocket 1, while pocket 2 was located on
the opposite side of the protein (Fig. 3). A comparison of the blinding affinities at the three different
binding pockets revealed that all of the hits for pocket 1 bind to the protein well, with binding
affinities of less than -10 kcal mol-1. This suggests that the pocket 1 is the most favorable for ligand
binding. In contrast, pocket 2 may not be a good location for binding compared to pockets 1 and 3
because it is associated with higher binding affinities. It is also interesting to note that some ligands
were repeated multiple times in the list of virtual screening results. These ligands can bind to
different pockets in different conformations (e.g.; the ligand NCI_127133 binds to pockets 1 and 2,
ligand NCI_670283 binds to pockets 1 and 3 and ligand NCI_293778 binds to pockets 1, 2 and 3).
These ligands may therefore have greater potential for use as inhibitors.
By analyzing the hydrogen bonding and hydrophobic interactions between the ligands and nsP3,
key residues were identified. The region encompassing residues 110-114 was predicted to be the
most important area for ligands interactions. This is consistent with the results of previous work by
Rungrotmongkol et al. [16].
Furthermore, equilibrium molecular dynamics simulations were carried out to validate the
molecular docking results. Analysis of the simulations confirmed that the docked ligand-nsP3
complexes were stable during the 20-ns simulation. However, subtle structural rearrangements in
nsP3 were observed that led to better accommodation of the ligands. MD simulations also
confirmed that the binding pocket 1 is the favored pocket for ligand binding, considering the
favorability of the interactions between the ligands and nsP3.

In summary, through a combination of molecular docking, virtual screening and molecular
dynamics simulations, we identified potential inhibitors of CHIKV based on the targeting of its
nsP3 macro domain. In the future work, the detailed binding modes for the identified inhibitors will
be better characterized by performing more computationally extensive free-energy calculations, and
their inhibitory effects will be verified by experimental studies. Additionally, the present work
provides useful information for constructing pharmacophores in ligand-based drug design and for
generating the chemical libraries utilized in the development of novel inhibitors targeting CHIKV.
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Figure 1. Re-docking ADP-ribose into the active site of nsP3: (A) The best docking pose of
ligand ADP-ribose is represented as a stick model (colored by atom type) while the protein
nsP3 is shown in the solvent surface (colored by interpolated charge with a probe radius of 1.4
Å). (B) The interactions of this pose and nsP3 residues showing hydrogen bonding
interactions at the binding site of nsP3.

Figure 2. Superimposition of the ADP-ribose after docking (in red, the top pose) on its
structure in the co-crystal structure (in blue) at the active site of nsP3. The heavy-atom
RMSD between them is about 0.6 Å.

Figure 3. Representation of three binding pockets identified in the nsP3: (A) The location of
three pockets in the nsP3. (B) Illustration of three pockets showing the locations of five top-hit
compounds obtained from virtual screenings at these binding sites: NCI_25457,
NCI_345647_a, NCI_61610 (in magenta) at the pocket 1, NCI_127133 (in blue) at the pocket 2
and NCI_670283 (in yellow) at the pocket 3.

Figure 4. Illustration of three binding pockets identified in the nsP3. Each illustration
contains two images: the first shows the protein nsP3 (in red) as a ribbon and the ligand (in
green) in stick representation, and the second shows the surface of the pocket (in purple)
surrounding the bound ligand (in green) in stick representation: (A) Pocket 1 with the
complex nsP3-NCI_61610. (B) Pocket 2 with the complex nsP3-NCI_127133 (structure has
been rotated 1800). (C) Pocket 3 with complex nsP3-NCI_670283.

Figure 5. Backbone RMSD profiles for the apoprotein nsP3 and its complexes of nsP3 with
various ligands during MD simulations.

Figure 6. RMSFs values of the Cα atoms of the apoprotein nsP3 and its different complexes,
as calculated during MD simulations.

Figure 7. Superimposition of complex structures observed at 0 ns (in blue) and 23 ns (in red)
with the structures represented as ribbons, the ligands as van der Waals surfaces, and the
residues surrounding the ligands as sticks: (A) Apoprotein nsP3. (B)-(F): Complexes of nsP3
with the ligands NCI_61610 (B), NCI_25457 (C), NCI_345647_a (D), NCI_670283 (E), and
NCI_127133 (F).

Figure 8. Hydrogen-bonding interactions between nsP3 and NCI_61610 and NCI_670283: (A)
The complex of nsP3 with ligand NCI_61610 involves three strong H-bonds with residues
Asn24, Tyr114 and Gly112. (B) The complex of nsP3 with ligand NCI_670283 involves one
strong H-bond with Thr111 and one moderately strong H-bond with Gly112.

Table 1. Comparison of the hydrogen-bonding interactions inferred for the nsP3-ADP-ribose
docked complex with previously published data. In [17], key residues were identified by
performing an experimental study of the crystal structures of the complex nsP3-ADP-ribose
(3GPO), while residues reported in [16] were determined by realizing molecular dynamics
simulations of ADP-ribose in nsP3, based on the above crystal structures.

HBs
Interacting residues

Current work
11
Ile11, Ala23, Asn24,
Asp31, Val33,
Leu108, Gly112,
Val113, Tyr114,
Tyr142, Arg144

Ref [17]
11
Asp10, Ile11, Asn24,
Asp31, Thr111,
Gly112, Val113,
Tyr114, Tyr142,
Arg144

Ref [16]
11
Asp10, Ile11, Asn24,
Asp31, Val33,
Ser110, Thr111
Gly112, Val113,
Tyr114, Arg144

Table 2. Chemical structures of the top five hit compounds and their properties.
Compound’s
name

Structural formula

Binding
affinitites
(kcal/mol)

Lipinski’s values

1

NCI-61610
(C34H24N6O2)

-11.1

LogP: 5.31
H-D: 4
H-A: 4
MW: 548.6

2

NCI-25457
(C24H16N2O)

-10.8

LogP: 5.5
H-D: 0
H-A: 3
MW: 348.39

3

NCI-345647_a
(C30H26O10)

-10.9

LogP: 5.9
H-D: 6
H-A: 10
MW: 546.52

4

NCI_670283
(C25H24O2)

-10.6

LogP: 4.5
H-D: 0
H-A: 2
MW: 356.45

5

NCI_127133
(C27H18N2O4)

-8.3

LogP: 4.52
H-D: 3
H-A:4
MW: 434.4

LogP: An octanol-water partition coefficient; H-D: Hydrogen donor; H-A: Hydrogen acceptor;
MW: Molecular weight.

Table 3. Analysis of the hydrogen bonds that occurred during the trajectories sampled in the
MD simulations.

NCI_61610

Number of H-bonds
5

NCI_25457

3

NCI_345647_a

7

NCI_670283

4

NCI_127133

0

Details of H-bonds
% occupancy
Asn24 (HD22)-O1
98
Tyr114 (HN)-O
92
Gly112 (HN)-O
88
Thr111 (OG1)-H1
13
Cys34 (HG1)-O1
10
Val113 (HN)-N
29
Val33 (HN)-N
21
Val33 (HN)-O
20
Ile11 (HN)-O4
39
Ile11 (HN)-O6
12
Gly112 (HN)-O1
18
Val33 (HN)-O
17
Gly32 (O)-O5
14
Thr111 (HN)-O1
13
Arg144 (HE)-O3
10
Thr111 (HN)-O
77
Gly112 (HN)-O
65
Ser110 (HN)-O
25
Thr111 (HG1)-O
10
No H-bonds with occupancy more than 10%

Table 4. Analysis of hydrophobic contacts during the trajectories sampled in the MD
simulations.
Ligand

NCI_61610
NCI_25457
NCI_345647_a
NCI_670283
NCI_127133

Number of
interacting
residues
8
6
6
6
3

Name of non-polar residues interactions

Ala22, Pro25, Leu28, Val33, Pro107, Val113, Tyr114, Trp148
Ala22, Val33, Pro107, Val113, Tyr114, Trp148
Ile11, Val33, Ala36, Val113, Tyr114, Trp148
Ala22, Leu28, Val33, Pro107, Val113, Tyr114
Ala1, Pro2, Tyr4

Table 5. SASA values obtained in the simulations of apo nsP3 and complexes of it with
different ligands.

Ala22
Pro25
Leu28
Val33
Pro107
Val113
Tyr114
Trp148
Ile11
Ala36
Ala1
Pro2
Tyr4

nsP3
31.3
75.5
102.6
68.8
25.9
129.8
70.2
84.0
12.6
34.0
74.5
37.9
39.2

nsP3NCI_61610
36.6
57.8
108.2
81.7
20.4
146.5
63.4
88.4

nsP3nsP3nsP3NCI_25457 NCI_345647_a NCI_670283
35.6
45.0

57.4
25.2
138.8
69.3
90.2

52.9
130.8
63.8
95.5
25.8
30.0

nsP3NCI_127133

100.8
79.7
24.1
142.2
87.4

81.2
56.4
41.7

Supporting information
Table S1. List of poses in the docking of ADP-ribose into nsP3. RMSD refers to the heavyatom root mean square deviation from the co-crystal structure for ADP-ribose.
Poses
1
2
3
4
5
6
7
8
9

Binding affinity (kcal/mol)
-10.2
-8.9
-8.9
-8.9
-8.6
-8.5
-8.4
-8.3
-7.8

RMSD (Å)
0.6
8.6
1.8
5.5
8.4
4.4
0.6
0.6
0.6

Table S2. Results of the top ten compounds of different runs.
VST1
Fit at the center
of binding site
Center_x = 9.7
Center_y =43.0
Center_z = -13.2

VST2
Fit at the center
of binding site
Center_x = 9.7
Center_y = 43.0
Center_z = -13.2

VST3
Fit at the center
of binding site
Center_x = 9.7
Center_y = 43.0
Center_z = -13.2

VST4
Fit at the center
of protein
Center_x = 7.7
Center_y = 45.3
Center_z = -5.3

Cover binding
site
Size 16×16×16
1.NCI_25457
(-10.8)
2.NCI_116702
(-10.7)
3.NCI_309892
(-10.3)
4.NCI_109451
(-10.2)
5.NCI_127133
(-10.2)
6.NCI_328101
(-10.2)
7.NCI_372275_a
(-10.2)
8.NCI_45545
(-10.2)
9.NCI_84100_b
(-10.2)
10.NCI_37168
(-10.1)

Cover
binding
site
Size 20×20×20
1.NCI_34567_a
(-10.9)
2.NCI_37553
(-10.9)
3.NCI_25457
(-10.8)
4.NCI_116702
(-10.7)
5.NCI_58052
(-10.6)
6.NCI_127133
(-10.5)
7.NCI_293778
(-10.5)
8.NCI_670283
(-10.5)
9.NCI_328101
(-10.4)
10.NCI_372499_b
(-10.3)

Cover the whole
protein
Size 50×50×56
1.NCI_61610
(-11.1)
2.NCI_293778
(-11.0)
3.NCI_345647_a
(-10.9)
4.NCI_25457
(-10.8)
5.NCI_58052
(-10.6)
6.NCI_127133
(-10.5)
7.NCI_372499_b
(-10.3)
8.NCI_37553
(-10.3)
9.NCI_309892
(-10.2)
10.NCI_37168
(-10.2)

Cover
the
whole protein
Size 50×50×56
1.NCI_61610
(-11.1)
2.NCI_37553
(-11.0)
3.NCI_345647_a
(-10.9)
4.NCI_25457
(-10.8)
5.NCI_293778
(-10.8)
6.NCI_127133
(-10.7)
7.NCI_116702
(-10.6)
8.NCI_58052
(-10.6)
9.NCI_670283
(-10.5)
10.NCI_324623
(-10.3)

VST5
Fit
at
the
prediction
pocket 2
Center_x = 7.7
Center_y = 45.4
Center_z = 11.5
Cover binding
site
Size 20×20×20
1.NCI_127133
(-8.3)
2.NCI_293778
(-8.2)
3.NCI_338042
(-7.6)
4.NCI_132232
(-7.5)
5.NCI_310326
(-7.4)
6.NCI_328101
(-7.4)
7.NCI_69359_a
(-7.3)
8.NCI_90737
(-7.3)
9.NCI_122819_a
(-7.2)
10.NCI_400976
(-7.2)

VST6
Fit
at
the
prediction
pocket 3
Center_x = 2.3
Center_y = 44.6
Center_z = -18.3
Cover binding
site
Size 20×20×20
1.NCI_670283
(-10.6)
2.NCI_319990
(-10.2)
3.NCI_80731
(-10.1)
4.NCI_84100_b
(-10.1)
5.NCI_372287_a
(-10.0)
6.NCI_84100_a
(-9.9)
7.NCI_97920
(-9.6)
8.NCI_58502
(-9.5)
9.NCI_227186_a
(-9.4)
10.NCI_293778
(-9.4)

Table S3. Re-docking results for complex nsP3-NCI_61610 with different conformations of
nsP3 taken from the different times of simulations at the pocket 1.
nsP3 conformation

Binding affinity
(kcal/mol)

Interaction between the inhibitor and
residues of protein (with distance in Å)

At 0ns

-11.1

At 5 ns
At 10 ns

-10.3
-11.3

At 15 ns

-10.6

At 20 ns

-11.4

Tyr114(HH)-N=2.0
Val33(HN)-O=2.3
Asn24(HD21)-O=2.4
Tyr114 (OH)-H1=1.9
Asn24 (HD22)-O=2.1
Tyr114 (OH)-H1=2.3
Asn24 (HD22)-O1=2.5
Ser110 (HN)-O=1.9
Tyr114 (OH)-H1=2.3

Table S4. Virtual screening results for blind docking into the pocket 1 with different
conformations of nsP3 taken from the different times of simulations.

VST-5ns
Fit at the center of
binding site
Center_x = 9.7
Center_y =43.0
Center_z = -13.2

VST-10ns
Fit at the center
binding site
Center_x = 9.7
Center_y = 43.0
Center_z = -13.2

Cover binding site
Size 20×20×20
1.NCI_293778
(-11.6)
2.NCI_84100_b
(-10.7)
3.NCI_84100_a
(-10.6)
4.NCI_80997_b
(-10.5)
5.NCI_37553
(-10.4)
6.NCI_61610
(-10.3)
7.NCI_670283
(-10.2)
8.NCI_59620_a
(-10.2)
9.NCI_308835
(-10.2)
10.NCI_60785_a
(-10.2)

Cover binding site
Size 20×20×20
1.NCI_37553
(-11.1)
2.NCI_293778
(-11.1)
3.NCI_60785_a
(-11.0)
4.NCI_ 59620_a
(-10.8)
5.NCI_27592_a
(-10.7)
6.NCI_670283
(-10.7)
7.NCI_82802_a
(-10.7)
8.NCI_328101
(-10.5)
9.NCI_59620_a
(-10.5)
10.NCI_308835
(-10.5)

of

VST-15ns
Fit at the center of
binding site
Center_x = 9.7
Center_y = 43.0
Center_z = -13.2

VST-20ns
Fit at the center of
binding site
Center_x = 9.7
Center_y = 43.0
Center_z = -13.2

Cover binding site
Size 20×20×20
1.NCI_293778
(-10.5)
2.NCI_308835
(-10.3)
3.NCI_37553
(-10.3)
4.NCI_97920
(-10.0)
5.NCI_84100_b
(-9.9)
6.NCI_59620_a
(-9.8)
7.NCI_84100_a
(-9.8)
8.NCI_37627
(-9.8)
9.NCI_60785_b
(-9.7)
10.NCI_25457
(-9.7)

Cover binding site
Size 20×20×20
1.NCI_37553
(-12.1)
2.NCI_61610
(-11.9)
3.NCI_670283
(-11.7)
4.NCI_293778
(-11.3)
5.NCI_60785_a
(-11.1)
6.NCI_63680
(-11.1)
7.NCI_82802_a
(-11.0)
8.NCI_219894
(-10.8)
9.NCI_80997_b
(-10.7)
10.NCI_328101
(-10.7)

Figure S1. Structure of nsP3 with location of three binding sites at the different virtual
screenings: (A) VST1; (B) VST2; (C) VST3; (D) VST4; (E) VST5; (F) VST6.

